Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZomedicaZOMDF +0.36% Debt-to-Equity is 0.02 as of Mar. 2026, which is 100% above its 10-year median of 0.01. The stock has 3 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Zomedica ranks better than 92.2% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Zomedica's Debt-to-Equity or its related term are showing as below:
ZOMDF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.77
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Zomedica was 0.77. The lowest was 0.00. And the median was 0.01.
ZOMDF's Debt-to-Equity is ranked better than 92.2% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs ZOMDF: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Zomedica Debt-to-Equity Related Terms
Zomedica Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Zomedica's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZOMDF vs STIM, OM, RPID: Debt-to-Equity Comparison
For the Medical Devices subindustry, Zomedica's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zomedica Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Zomedica's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zomedica (ZOMDF) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zomedica and its competitors. This is 100% above median its historical median of 0.01. According to the industry distribution chart, Zomedica ranks #55 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 7.8%.
Is Zomedica's Debt-to-Equity too high?
Zomedica's current Debt-to-Equity of 0.02 is 100% above median its 10-year median of 0.01. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Zomedica's value of 0.02 is 91.3% below this industry median. Based on the distribution chart, Zomedica ranks #55 out of 705 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Zomedica's Debt-to-Equity compare to STIM and OM?
According to the Medical Devices & Instruments industry distribution chart, Zomedica ranks #55 out of 705 companies for Debt-to-Equity. This places Zomedica in the top 8% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Zomedica's value of 0.02 is 91.3% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.23, Zomedica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zomedica's current Debt-to-Equity of 0.02 is 91.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zomedica and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zomedica's current Debt-to-Equity is 0.02, which is 100% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zomedica stock overvalued right now?
Based on GuruFocus' analysis, Zomedica (ZOMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.19, compared to a current price of $0.09 — trading 54.1% below its estimated fair value. The current Debt-to-Equity is 0.02, which is 100% above median its 10-year median of 0.01 and 91.3% below the Medical Devices & Instruments industry median of 0.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Zomedica (ZOMDF), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZOMDF has been successfully added to your 
